Atlas Trials

Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine

Clinical trial NCT01392079 · COMPLETED

Trial details

NCT number
NCT01392079
Sponsor
University of Ulm
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2008-02-01
Primary completion
2012-01-01
Enrollment
135

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.